Nektar Therapeutics (NKTR) Net Income towards Common Stockholders (2010 - 2026)

Nektar Therapeutics' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$43.2 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 7.04% year-over-year to -$43.2 million; the TTM figure through Mar 2026 stood at -$117.7 million (down 13.44% YoY), while the FY2025 annual figure was -$121.0 million, down 28.5% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$43.2 million, down from -$386000.0 in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $32.1 million in Q4 2024, with the low at -$159.1 million in Q2 2022.
• The 5-year median for Net Income towards Common Stockholders is -$43.2 million (2026), against an average of -$48.4 million.
• The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders slumped 308.58% in 2023, then soared 176.18% in 2024.
• Nektar Therapeutics' Net Income towards Common Stockholders stood at $20.2 million in 2022, then plunged by 308.58% to -$42.1 million in 2023, then soared by 176.18% to $32.1 million in 2024, then tumbled by 101.2% to -$386000.0 in 2025, then plunged by 11079.79% to -$43.2 million in 2026.
• Business Quant data shows NKTR's Net Income towards Common Stockholders at -$43.2 million in Q1 2026, -$386000.0 in Q4 2025, and -$35.0 million in Q3 2025.